Cambridge Antibody, Xerion Pharmaceuticals GmbH deal

CAT and Xerion expanded a 2001 deal under which CAT licensed to Xerion its human phage antibody libraries and IP for target discovery, target validation and functional proteomics. As expanded, the com...